Valganciclovir for symptomatic congenital cytomegalovirus disease.

W Kimberlin, David; M Jester, Penelope; J Sánchez, Pablo; Ahmed, Amina; Arav-Boger, Ravit; G Michaels, Marian; Ashouri, Negar; A Englund, Janet; Estrada, Benjamin; F Jacobs, Richard; R Romero, José; K Sood, Sunil; Suzanne Whitworth, M; J Abzug, Mark; T Caserta, Mary; Fowler, Sandra; Lujan-Zilbermann, Jorge; A Storch, Gregory; L DeBiasi, Roberta; Han, Jin-Young; Palmer, April; B Weiner, Leonard; A Bocchini, Joseph; H Dennehy, Penelope; Finn, Adam; D Griffiths, Paul; Luck, Suzanne; Gutierrez, Kathleen; Halasa, Natasha; Homans, James; L Shane, Andi; Sharland, Michael; Simonsen, Kari; A Vanchiere, John; R Woods, Charles; L Sabo, Diane; Aban, Inmaculada; Kuo, Huichien; H James, Scott; N Prichard, Mark; Griffin, Jill; Giles, Dusty; P Acosta, Edward; J Whitley, Richard; Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group, National

doi:10.1056/nejmoa1404599

Public

Valganciclovir for symptomatic congenital cytomegalovirus disease.

Shared by NobleBlocks on Mar 5, 2015 • 12:00 AM UTC

Authors:

David W Kimberlin

Penelope M Jester

Pablo J Sánchez

Abstract

BACKGROUND: The treatment of symptomatic congenital cytomegalovirus (CMV) disease with intravenous ganciclovir for 6 weeks has been shown to improve audiologic outcomes at 6 months, but the benefits wane over time. METHODS: We conducted a randomized, placebo-controlled trial of valganciclovir therap...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!